Literature DB >> 20399450

Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma.

Tobias Klatte1, Christine Anterasian, Jonathan W Said, Michela de Martino, Fairooz F Kabbinavar, Arie S Belldegrun, Allan J Pantuck.   

Abstract

PURPOSE: Recent evidence suggests that nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma. We tested this hypothesis in an independent large series from a single institution.
MATERIALS AND METHODS: One dedicated uropathologist regraded 158 cases of papillary renal cell carcinoma by nucleolar and Fuhrman grades. The prognostic value and predictive accuracy of these grading systems to predict disease specific survival were analyzed by Cox proportional hazards models and the concordance index.
RESULTS: There were 39 papillary renal cell carcinoma related deaths (25%) at a mean followup of 50 months. On univariate analysis nucleolar grade predicted disease specific survival with a concordance index of 67.8% but the survival difference between grades 1 and 2 did not attain statistical significance (p = 0.1441). Fuhrman grade predicted disease specific survival significantly better (concordance index 74.7%, p <0.001). Comparison of survival estimates between the grades revealed statistical significance across each grade category (each p <0.05). Fuhrman but not nucleolar grade was retained as an independent prognostic factor on multivariate analysis (p = 0.027 and 0.128, respectively).
CONCLUSIONS: Each grading system performs well but the predictive accuracy of Fuhrman grade is statistically superior to that of nucleolar grade and only Fuhrman grade provides independent prognostic information on patients with papillary renal cell carcinoma. Thus, Fuhrman grade should be the standard grading system for papillary renal cell carcinoma. Copyright 2010 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20399450     DOI: 10.1016/j.juro.2010.02.023

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.600


  7 in total

1.  Fuhrman grading is inappropriate for papillary renal cell carcinoma.

Authors:  Brett Delahunt; Lars Egevad; John R Srigley; Hemamali Samaratunga
Journal:  World J Urol       Date:  2017-12-18       Impact factor: 4.226

2.  Prognostic significance of Fuhrman grade and age for cancer-specific and overall survival in patients with papillary renal cell carcinoma: results of an international multi-institutional study on 2189 patients.

Authors:  H Borgmann; M Musquera; A Haferkamp; A Vilaseca; T Klatte; S F Shariat; A Scavuzzo; M A Jimenez Rios; I Wolff; U Capitanio; P Dell'Oglio; L M Krabbe; E Herrmann; T Ecke; D Vergho; N Huck; N Wagener; S Pahernik; S Zastrow; M Wirth; C Surcel; C Mirvald; K Prochazkova; G Hutterer; R Zigeuner; L Cindolo; M Hora; C G Stief; M May; S D Brookman-May
Journal:  World J Urol       Date:  2017-08-23       Impact factor: 4.226

3.  Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.

Authors:  Alcides Chaux; Luciana Schultz; Roula Albadine; Jessica Hicks; Jenny J Kim; Mohamad E Allaf; Michael A Carducci; Ronald Rodriguez; Hans-Joerg Hammers; Pedram Argani; Victor E Reuter; George J Netto
Journal:  Hum Pathol       Date:  2012-04-26       Impact factor: 3.466

4.  Prognostic implications of the magnetic resonance imaging appearance in papillary renal cell carcinoma.

Authors:  Andrew B Rosenkrantz; Aarti Sekhar; Elizabeth M Genega; Jonathan Melamed; James S Babb; Amish D Patel; Andy Lo; Robert M Najarian; Muneeb Ahmed; Ivan Pedrosa
Journal:  Eur Radiol       Date:  2012-08-21       Impact factor: 5.315

5.  Clinically localized type 1 and 2 papillary renal cell carcinomas have similar survival outcomes following surgery.

Authors:  Rodrigo A Ledezma; Edris Negron; Gladell P Paner; Chris Rjepaj; Danny Lascano; Mohammed Haseebuddin; Pankaj Dangle; Arieh L Shalhav; Henry Crist; Jay D Raman; G Joel DeCastro; Lara Harik; Monika Paroder; Robert G Uzzo; Alexander Kutikov; Scott E Eggener
Journal:  World J Urol       Date:  2015-09-25       Impact factor: 4.226

6.  Papillary renal cell carcinoma revisited: a comprehensive histomorphologic study with outcome correlations.

Authors:  Joshua I Warrick; Alex Tsodikov; Lakshmi P Kunju; Arul M Chinnaiyan; Ganesh S Palapattu; Todd M Morgan; Ajjai Alva; Scott Tomlins; Angela Wu; Jeffrey S Montgomery; Khaled S Hafez; J Stuart Wolf; Alon Z Weizer; Rohit Mehra
Journal:  Hum Pathol       Date:  2014-02-20       Impact factor: 3.466

7.  Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.

Authors:  Rola M Saleeb; Mina Farag; Zsuzsanna Lichner; Fadi Brimo; Jenni Bartlett; Georg Bjarnason; Antonio Finelli; Fabio Rontondo; Michelle R Downes; George M Yousef
Journal:  Mol Oncol       Date:  2018-08-23       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.